Is FOXO Technologies Inc. (FOXO) a Buy, Sell, or Hold?
OTC : FOXO
FOXO Technologies Inc.
$0.055 USD
-$0.01 (-21.43%)
- Volume
- 3.56K
- Average Volume
- 19.78K
- Market Capitalization
- $549.79K
- P/E Ratio
- -0.08
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.12
- Year Low
- $0.02
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.14
Company Overview
OTC
Seamus Lagan
Medical - Healthcare Information Services
Healthcare
FOXO
230
US
USD
Liquidity Metrics
1.25
0.14
0.14
0.00
0.00
Sales & Valuation
$16.37M
0.03
17.63
-0.22
0.00
Profitability
-$0.13
-$12.43M
-72.23%
-73.31%
-96.85%
-28.97%
P/E Metrics
-0.08
0.01
0.01
Analyst Price Target & Rating
1/5
0 Analysts
%
Financial Health Scores
-7.93
4/9
-$27.07M
$45.79M
$36.15M
-$9.95M
Key Metrics (TTM)
$12.81M
0.70
-1.35
0.14
-96.85%
-38.21%
-6.09%
-353.38%
-216 days
Company Executives
| Name | Title |
|---|---|
| Celene Laurene Rattray Grant | Chief Financial Officer & Principal Financial and Accounting Officer |
| Seamus Lagan | Chief Executive Officer & Director |
Poll Results
No votes yet today — be the first to share your view!
About FOXO Technologies Inc. (OTC:FOXO) Stock
FOXO Technologies Inc. operates as a technology platform company primarily focused on translating longevity science into practical applications for the life insurance sector. The firm is actively creating products and services that integrate scientific understanding of longevity with life insurance offerings. The dual objectives of these innovations are to encourage greater consumer involvement in their health and wellness, and to streamline the often-complex insurance underwriting process for customers. Among its key offerings is FOXO Labs, a service-oriented platform that enhances the customer underwriting experience by incorporating saliva-based epigenetic biomarkers into expedited underwriting procedures. Additionally, the company provides FOXO Life, an insurance products platform. Thi ... s platform offers a combination of FOXO's own unique life insurance products and policies from third-party carriers, all designed to bundle longevity science with life insurance. FOXO Technologies Inc. was established in 2019 and is headquartered in Minneapolis, Minnesota.
FOXO TECHNOLOGIES INC.'S SUBSIDIARY VECTOR BIOSOURCE, INC.
2026-07-29 08:30:00
WEST PALM BEACH, FL, July 29, 2026 (GLOBE NEWSWIRE) -- FOXO Technologies Inc.'s (OTC: FOXOD/FOXO) ( “FOXO”) subsidiary, Vector BioSource, Inc. (“Vector”) today announced that it has entered into a definitive agreement to acquire four U.S.-based blood collection centers (the “Agreement”) from Grifols Bio Supplies, Inc., a U.S.-based subsidiary of Grifols S.A. The acquisition is intended to provide a proprietary source of bio-products to sell to Vector's customers to augment its existing sourcing model. Furthermore, the new FDA licensure that Vector expects to be required is anticipated to further expand Vector's accessible market.
FOXO TECHNOLOGIES INC. CEO SEAMUS LAGAN PROVIDES MID-YEAR UPDATE TO SHAREHOLDERS
2026-07-06 09:07:00
WEST PALM BEACH, FL, July 06, 2026 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (OTC: FOXOD/FOXO) (the "Company") announces the following mid-year update to shareholders by the Company's Chief Executive Officer Seamus Lagan. FOXO Shareholders: As we have reached the mid-year point of the year, I wanted to provide our shareholders with an update on achievements for the first six months of 2026 and preview our go-forward operating and growth strategy for the remainder of the year and on a longer-term basis.
FOXO TECHNOLOGIES INC. CEO SEAMUS LAGAN PROVIDES MID-YEAR UPDATE TO SHAREHOLDERS
2026-07-06 09:07:00
WEST PALM BEACH, FL, July 06, 2026 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (OTC: FOXOD/FOXO) (the “Company”) announces the following mid-year update to shareholders by the Company's Chief Executive Officer Seamus Lagan.
FOXO TECHNOLOGIES INC. ANNOUNCES COMPLETION OF REVERSE STOCK SPLIT
2026-07-01 07:30:00
WEST PALM BEACH, FLORIDA, July 01, 2026 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (OTC: FOXO) (“FOXO” or the “Company”), today announced that its previously approved reverse stock split (the “Reverse Split”) of its Class A common stock (“Common Stock” and the “Reverse Split”) became effective at 4:01 p.m. ET on June 30, 2026 (the “Effective Time”). The Company's Common Stock will begin trading on a split-adjusted basis on the OTC under the temporary symbol “FOXOD” when the market opens on July 1, 2026, and will trade under a new CUSIP number (351471602). The trading symbol will revert to “FOXO” on or about July 20, 2026 (approximately 20 business days after the Effective Time).
FOXO TECHNOLOGIES, INC., FORMS STRATEGIC PARTNERSHIP WITH LONGEVITYFP TECHNOLOGIES, LLC.
2026-05-28 08:33:00
WEST PALM BEACH, FL and MINNETONKA, MN, May 28, 2026 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (OTC: FOXO) (the “Company”) and LongevityFP Technologies, LLC. (“LFP”) today jointly announced a strategic partnership to commercialize the Company's pioneering epigenetics technology. The partnership is in the form of an exclusive license agreement (the “Agreement”) whereby the Company's epigenetics-related technology including the Company's two patents and related intellectual property, will be licensed to LFP.
2026-05-28 08:33:00
WEST PALM BEACH, FL and MINNETONKA, MN, May 28, 2026 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (OTC: FOXO) (the "Company") and LongevityFP Technologies, LLC. ("LFP") today jointly announced a strategic partnership to commercialize the Company's pioneering epigenetics technology. The partnership is in the form of an exclusive license agreement (the "Agreement") whereby the Company's epigenetics-related technology including the Company's two patents and related intellectual property, will be licensed to LFP.
Frequently Asked Questions
-
What is the current FOXO Technologies Inc. (FOXO) stock price?
-
FOXO Technologies Inc.(OTC:FOXO) stock price is $0.055 in the last trading session. During the trading session, FOXO stock reached the peak price of $0.1199 while $0.0205 was the lowest point it dropped to. The percentage change in FOXO stock occurred in the recent session was --21.43% while the dollar amount for the price change in FOXO stock was -$0.01.
-
FOXO's industry and sector of operation?
-
The OTC listed FOXO is part of Medical - Healthcare Information Services industry that operates in the broader Healthcare sector.
-
Who are the executives of FOXO?
-
Celene Laurene Rattray Grant | Chief Financial Officer & Principal Financial and Accounting Officer
Seamus Lagan | Chief Executive Officer & Director
|
|
| -
How many employees does FOXO have?
-
Number of FOXO employees currently stands at 230. FOXO operates from 477 South Rosemary Ave., West Palm Beach, FL 33401, US.
-
Link for FOXO official website?
-
Official Website of FOXO is: https://www.foxotechnologies.com
-
How do I contact FOXO?
-
FOXO could be contacted at phone #612-562-9447 and can also be accessed through its website. FOXO operates from 477 South Rosemary Ave., West Palm Beach, FL 33401, US.
-
How many shares of FOXO are traded daily?
-
The average number of FOXO shares traded daily for last 3 months was 19.78K.
-
What is the market cap of FOXO currently?
-
The market value of FOXO currently stands at $549.79K with its latest stock price at $0.055